• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
AIM HY

AIM HY

  • Home
  • About AIM HY
  • Our research
    • Genetics
    • Biostatistics
    • Clinical Trial
    • Multi-omics
    • Mechanisms
    • Global Health
    • Health Economics
  • Consortium Members
  • Clinical Trial – AIM HY INFORM
    • Patients
    • The Patient Forum Comments Form
    • Staff
  • Publications
  • Contact Us
  • Internal

Our Research

AIM HY Consortium Lead, Professor Phil Chowienczyk speaks about AIM HY study.

Hypertension is recognised as the biggest contributor to the global burden of disease, a burden that is particularly great in ethnic minorities in the UK and in lower and middle-income countries (LMIC).

The objectives of the AIM HY consortium are to personalize the selection of established drugs to provide a more effective treatment of hypertension for ethnic minority groups in the UK and in LMIC populations such as Africa. The ultimate aim is personalization of treatment according to an objective blood test that captures the environmental and genetic determinants of response to treatment within ethnically diverse and admixed populations.

Goals of the Consortium

  • Identification of AIM and/or metabolites predicting response to treatment in existing multi-ethnic cohorts as “proof-of-concept”.
  • Optimal step one and two treatment for ethnic minorities in the UK in whom the need for effective blood pressure control is greatest.
  • AIM/metabolite prediction of a personalized step one and step two treatment in a clinical setting using either a single drug or combination of two drugs.
  • Identifying mechanisms that determine response to first line single drug and combination therapy and “drugable” targets for resistant hypertension.
  • Identifying groups likely to respond to non-standard combinations of existing drugs and new classes of anti-hypertensive agents.
  • A bioresource of patients in these groups in whom new approaches/novel drugs can be examined.
  • Predicting optimal treatment in lower and middle-income countries (LMIC).
Share your comments on “your life with hypertension” and/or your experience of AIM HY INFORM Clinical Trial.

” I was diagnosed with high blood pressure more than 10 years ago. In August 2015, I had a Coronary Angioplasty surgery when three stents were inserted in one of my heart’s arteries. My symptoms improved a bit but not significantly. In August 2017, I saw an advert inviting people to participate in the AIM HY programme. I hurriedly offered myself as a guinea-pig. I have only started the first round of dual therapy and believe me, I am feeling so much better.

For the first time in many years, I ran to catch a bus without feeling short of breath. I have opted to be an ambassador of this programme because it is effective.

If you would like to leave a comment related to your treatment or the AIM HY INFORM trial experience, please click here. 

The Consortium

British Heart Foundation Logo
Medical Research Council Logo
Queen Mary College London Logo
University of Cambridge Logo
University of Florida Logo
University of Glasgow logo
University of Kentucky logo
Manchester University logo
University of Nottingham

Copyright © 2023 · AIM HY · All Rights Reserved